BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating

Reuters2025-02-25

** BofA Global Research starts coverage on insulin device maker Beta Bionics BBNX.O with "buy" rating and $25 PT, citing its "differentiated closed-loop algorithm" that simplifies insulin-dosing for diabetic patients

** PT represents a 21.4% upside to stock's last close

** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years

** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA

** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026

** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2514709525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514709525","market":"us","top_or_hot":-1,"title":"BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating</title></head><body><p>** BofA Global Research starts coverage on insulin device maker Beta Bionics <span>BBNX.O</span> with \"buy\" rating and $25 PT, citing its \"differentiated closed-loop algorithm\" that simplifies insulin-dosing for diabetic patients</p><p>** PT represents a 21.4% upside to stock's last close</p><p>** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years</p><p>** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA</p><p>** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026</p><p>** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-25 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating</title></head><body><p>** BofA Global Research starts coverage on insulin device maker Beta Bionics <span>BBNX.O</span> with \"buy\" rating and $25 PT, citing its \"differentiated closed-loop algorithm\" that simplifies insulin-dosing for diabetic patients</p><p>** PT represents a 21.4% upside to stock's last close</p><p>** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years</p><p>** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA</p><p>** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026</p><p>** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAC","symbol_name":"美国银行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG140:1","article_id":"2514709525","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514709525","pubTimestamp":1740487363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating** BofA Global Research starts coverage on insulin device maker Beta Bionics BBNX.O with \"buy\" rating and $25 PT, citing its \"differentiated closed-loop algorithm\" that simplifies insulin-dosing for diabetic patients** PT represents a 21.4% upside to stock's last close** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BAC":"美国银行","BBNX":"Beta Bionics, Inc."},"translate_title":"BUZZ-美国银行开始对胰岛素设备制造商Beta Bionics给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBNX":0.9,"BAC":0.9},"content_text":"BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating** BofA Global Research starts coverage on insulin device maker Beta Bionics BBNX.O with \"buy\" rating and $25 PT, citing its \"differentiated closed-loop algorithm\" that simplifies insulin-dosing for diabetic patients** PT represents a 21.4% upside to stock's last close** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514709525","isCrawlerRequest":true}